|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kang SY, Kim YS, Kim Z, Kim HY, Kim HJ,
Park S, Bae SY, Yoon KH, Lee SB, Lee SK, et al: Breast cancer
statistics in Korea in 2017: Data from a breast cancer registry. J
Breast Cancer. 23:115–128. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Redig AJ and McAllister SS: Breast cancer
as a systemic disease: A view of metastasis. J Intern Med.
274:113–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leber MF and Efferth T: Molecular
principles of cancer invasion and metastasis (review). Int J Oncol.
34:881–895. 2009.PubMed/NCBI
|
|
7
|
Jiang WG, Sanders AJ, Katoh M, Ungefroren
H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P,
et al: Tissue invasion and metastasis: Molecular, biological and
clinical perspectives. Semin Cancer Biol. 35 (Suppl 1):S244–S275.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Zijl F, Krupitza G and Mikulits W:
Initial steps of metastasis: Cell invasion and endothelial
transmigration. Mutat Res. 728:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Treon SP, Tripsas CK, Meid K, Warren D,
Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, et al:
Ibrutinib in previously treated Waldenström's macroglobulinemia. N
Engl J Med. 372:1430–1440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cao Y, Yang G, Hunter ZR, Liu X, Xu L,
Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, et al:
The BCL2 antagonist ABT-199 triggers apoptosis, and augments
ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type
and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J
Haematol. 170:134–138. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pal Singh S, Dammeijer F and Hendriks RW:
Role of Bruton's tyrosine kinase in B cells and malignancies. Mol
Cancer. 17:572018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim HO: Development of BTK inhibitors for
the treatment of B-cell malignancies. Arch Pharm Res. 42:171–181.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mohamed AJ, Yu L, Bäckesjö CM, Vargas L,
Faryal R, Aints A, Christensson B, Berglöf A, Vihinen M, Nore BF
and Smith CI: Bruton's tyrosine kinase (Btk): Function, regulation,
and transformation with special emphasis on the PH domain. Immunol
Rev. 228:58–73. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lampson BL and Brown JR: Are BTK and PLCG2
mutations necessary and sufficient for ibrutinib resistance in
chronic lymphocytic leukemia? Expert Rev Hematol. 11:185–194. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Halcomb KE, Contreras CM, Hinman RM,
Coursey TG, Wright HL and Satterthwaite AB: Btk and phospholipase C
gamma 2 can function independently during B cell development. Eur J
Immunol. 37:1033–1042. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wilde JI and Watson SP: Regulation of
phospholipase C gamma isoforms in haematopoietic cells: Why one,
not the other? Cell Signal. 13:691–701. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koivunen J, Aaltonen V and Peltonen J:
Protein kinase C (PKC) family in cancer progression. Cancer Lett.
235:1–10. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Isakov N: Protein kinase C (PKC) isoforms
in cancer, tumor promotion and tumor suppression. Semin Cancer
Biol. 48:36–52. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grabinski N and Ewald F: Ibrutinib
(ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and
cell viability of ErbB2-positive breast cancer cells. Invest New
Drugs. 32:1096–1104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Kinoshita T, Sukbuntherng J, Chang
BY and Elias L: Ibrutinib Inhibits ERBB receptor tyrosine kinases
and HER2-amplified breast cancer cell growth. Mol Cancer Ther.
15:2835–2844. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stetler-Stevenson WG, Hewitt R and
Corcoran M: Matrix metalloproteinases and tumor invasion: From
correlation and causality to the clinic. Semin Cancer Biol.
7:147–154. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Itoh Y and Nagase H: Matrix
metalloproteinases in cancer. Essays Biochem. 38:21–36. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brinckerhoff CE and Matrisian LM: Matrix
metalloproteinases: A tail of a frog that became a prince. Nat Rev
Mol Cell Biol. 3:207–214. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weng CJ, Chau CF, Hsieh YS, Yang SF and
Yen GC: Lucidenic acid inhibits PMA-induced invasion of human
hepatoma cells through inactivating MAPK/ERK signal transduction
pathway and reducing binding activities of NF-kappaB and AP-1.
Carcinogenesis. 29:147–156. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vandooren J, Van den Steen PE and
Opdenakker G: Biochemistry and molecular biology of gelatinase B or
matrix metalloproteinase-9 (MMP-9): The next decade. Crit Rev
Biochem Mol Biol. 48:222–272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scorilas A, Karameris A, Arnogiannaki N,
Ardavanis A, Bassilopoulos P, Trangas T and Talieri M:
Overexpression of matrix-metalloproteinase-9 in human breast
cancer: A potential favourable indicator in node-negative patients.
Br J Cancer. 84:1488–1496. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roomi MW, Kalinovsky T, Rath M and
Niedzwiecki A: Modulation of MMP-2 and MMP-9 secretion by
cytokines, inducers and inhibitors in human glioblastoma T-98G
cells. Oncol Rep. 37:1907–1913. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Newton AC: Regulation of protein kinase C.
Curr Opin Cell Biol. 9:161–167. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin CW, Hou WC, Shen SC, Juan SH, Ko CH,
Wang LM and Chen YC: Quercetin inhibition of tumor invasion via
suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9
activation in breast carcinoma cells. Carcinogenesis. 29:1807–1815.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee SO, Jeong YJ, Kim M, Kim CH and Lee
IS: Suppression of PMA-induced tumor cell invasion by capillarisin
via the inhibition of NF-kappaB-dependent MMP-9 expression. Biochem
Biophys Res Commun. 366:1019–1024. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Noh EM, Park YJ, Kim JM, Kim MS, Kim HR,
Song HK, Hong OY, So HS, Yang SH, Kim JS, et al: Fisetin regulates
TPA-induced breast cell invasion by suppressing matrix
metalloproteinase-9 activation via the PKC/ROS/MAPK pathways. Eur J
Pharmacol. 764:79–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim JM, Noh EM, Kwon KB, Kim JS, You YO,
Hwang JK, Hwang BM, Kim BS, Lee SH, Lee SJ, et al: Curcumin
suppresses the TPA-induced invasion through inhibition of
PKCα-dependent MMP-expression in MCF-7 human breast cancer cells.
Phytomedicine. 19:1085–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim HR, Kim JM, Kim MS, Hwang JK, Park YJ,
Yang SH, Kim HJ, Ryu DG, Lee DS, Oh H, et al: Saussurea lappa
extract suppresses TPA-induced cell invasion via inhibition of
NF-κB-dependent MMP-9 expression in MCF-7 breast cancer cells. BMC
Complement Altern Med. 14:1702014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park SY, Kim YH, Kim Y and Lee SJ:
Frondoside A has an anti-invasive effect by inhibiting TPA-induced
MMP-9 activation via NF-κB and AP-1 signaling in human breast
cancer cells. Int J Oncol. 41:933–940. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park SH, Kim JH, Lee DH, Kang JW, Song HH,
Oh SR and Yoon DY: Luteolin 8-C-β-fucopyranoside inhibits invasion
and suppresses TPA-induced MMP-9 and IL-8 via ERK/AP-1 and
ERK/NF-κB signaling in MCF-7 breast cancer cells. Biochimie.
95:2082–2090. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Roskoski R Jr: ERK1/2 MAP kinases:
Structure, function, and regulation. Pharmacol Res. 66:105–143.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y and
Hu LL: ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med.
19:1997–2007. 2020.PubMed/NCBI
|
|
38
|
Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC
and Lee IS: Silibinin suppresses PMA-induced MMP-9 expression by
blocking the AP-1 activation via MAPK signaling pathways in MCF-7
human breast carcinoma cells. Biochem Biophys Res Commun.
354:165–171. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim JM, Noh EM, Song HK, You YO, Jung SH,
Kim JS, Kwon KB, Lee YR and Youn HJ: Silencing of casein kinase 2
inhibits PKC-induced cell invasion by targeting MMP-9 in MCF-7
cells. Mol Med Rep. 17:8397–8402. 2018.PubMed/NCBI
|
|
40
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Duffy MJ, Maguire TM, Hill A, McDermott E
and O'Higgins N: Metalloproteinases: Role in breast carcinogenesis,
invasion and metastasis. Breast Cancer Res. 2:252–257. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Woessner JF Jr: Matrix metalloproteinases
and their inhibitors in connective tissue remodeling. FASEB J.
5:2145–2154. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yousef EM, Tahir MR, St-Pierre Y and
Gaboury LA: MMP-9 expression varies according to molecular subtypes
of breast cancer. BMC Cancer. 14:6092014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Roskoski R Jr: RAF
protein-serine/threonine kinases: Structure and regulation. Biochem
Biophys Res Commun. 399:313–317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Roskoski R Jr: MEK1/2 dual-specificity
protein kinases: Structure and regulation. Biochem Biophys Res
Commun. 417:5–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Roskoski R Jr: A historical overview of
protein kinases and their targeted small molecule inhibitors.
Pharmacol Res. 100:1–23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hendriks RW, Yuvaraj S and Kil LP:
Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev
Cancer. 14:219–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Buggy JJ and Elias L: Bruton tyrosine
kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol.
31:119–132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kawakami T, Kawakami Y and Kitaura J:
Protein kinase C beta (PKC beta): Normal functions and diseases. J
Biochem. 132:677–682. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang J, Anastasiadis PZ, Liu Y, Thompson
EA and Fields AP: Protein kinase C (PKC) betaII induces cell
invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling
pathway. J Biol Chem. 279:22118–22123. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Barry OP and Kazanietz MG: Protein kinase
C isozymes, novel phorbol ester receptors and cancer chemotherapy.
Curr Pharm Des. 7:1725–1744. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kazanietz MG: Novel ‘nonkinase’ phorbol
ester receptors: The C1 domain connection. Mol Pharmacol.
61:759–767. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Urtreger AJ, Kazanietz MG and Bal de Kier
Joffé ED: Contribution of individual PKC isoforms to breast cancer
progression. IUBMB Life. 64:18–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chakraborti S, Mandal M, Das S, Mandal A
and Chakraborti T: Regulation of matrix metalloproteinases: An
overview. Mol Cell Biochem. 253:269–285. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Qi M and Elion EA: MAP kinase pathways. J
Cell Sci. 118:3569–3572. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yao J, Xiong S, Klos K, Nguyen N, Grijalva
R, Li P and Yu D: Multiple signaling pathways involved in
activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1
in human breast cancer cells. Oncogene. 20:8066–8074. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Whitmarsh AJ: Regulation of gene
transcription by mitogen-activated protein kinase signaling
pathways. Biochim Biophys Acta. 1773:1285–1298. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jiang N, Dai Q, Su X, Fu J, Feng X and
Peng J: Role of PI3K/AKT pathway in cancer: The framework of
malignant behavior. Mol Biol Rep. 47:4587–4629. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Karin M: The regulation of AP-1 activity
by mitogen-activated protein kinases. J Biol Chem. 270:16483–16486.
1995. View Article : Google Scholar : PubMed/NCBI
|
